Showing results (2471-2480 of 2,674) with videos related to

Sort By:
Pageof 268
Plos One|June 3, 2022
Evaluation of strategies to modify Anti-SARS-CoV-2 monoclonal antibodies for optimal functionality as therapeuticsRobert V House, Thomas A Broge, Todd J Suscovich, et al.
European Urology Open Science|November 13, 2023
Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial CarcinomaEnrique Grande, Aristotelis Bamias, Matthew D Galsky, et al.
Bioorganic & Medicinal Chemistry Letters|October 23, 2020
Azepino-indazoles as calcitonin gene-related peptide (CGRP) receptor antagonistsStephen E Mercer, Prasad V Chaturvedula, Charles M Conway, et al.
Bioorganic & Medicinal Chemistry Letters|June 7, 2015
Biaryls as potent, tunable dual neurokinin 1 receptor antagonists and serotonin transporter inhibitorsAndrew P Degnan, George O Tora, Ying Han, et al.
Annals of the American Thoracic Society|April 13, 2016
Clinical Features and Associated Likelihood of Primary Ciliary Dyskinesia in Children and AdolescentsMargaret W Leigh, Thomas W Ferkol, Stephanie D Davis, et al.
Bioorganic & Medicinal Chemistry Letters|February 14, 2013
The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 2Xiaojun Han, Rita L Civiello, Charles M Conway, et al.
BJU International|June 5, 2014
A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trialMaria Pearse, Carol Fraser-Browne, Ian D Davis, et al.
Annals of the American Thoracic Society|November 7, 2022
Laterality Defects in Primary Ciliary Dyskinesia: Relationship to Ultrastructural Defect or GenotypeAndrew T Barber, Adam J Shapiro, Stephanie D Davis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigenAndrew M Scott, Niall Tebbutt, Fook-Thean Lee, et al.
European Urology|October 25, 2016
Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic CategoryIan D Davis, Wanling Xie, Carmel Pezaro, et al.
Pageof 268